Company intelligence / Profile preview
Aptose Biosciences Inc.
Toronto, Ontario, Canadaaptose.com ↗
- Ownership
- Public · APTO
- Development stage
- Phase 2
01
Overview
Tuspetinib-based triple therapy (TUS+VEN+AZA) has shown promising early results in newly diagnosed AML patients, including complete remissions in difficult-to-treat TP53-mutated AML and FLT3-wildtype AML patients. The TUSCANY Phase 1/2 trial is ongoing with patients being treated at the 80 mg TUS dose level after successful completion of the 40 mg dose cohort.
- Therapeutic areas
- OncologyHematology
- Modalities
- Small molecule kinase inhibitors
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Hanmi PharmaceuticalNational Cancer Institute (CRADA)
Beyond the preview
Go deeper on Aptose Biosciences Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aptose Biosciences Inc..